The Impact of Age on Non-Small Cell Lung Cancer: A Comprehensive Overview

3rd International Conference on Chemo and BioInformatics, Kragujevac, September 25-26. 2025. (pp. 269-272) 

 

АУТОР(И) / AUTHOR(S):Jasmina M. Obradovic, Olgica Mihaljević

 

Download Full Pdf   

DOI:  10.46793/ICCBIKG25.269O

САЖЕТАК / ABSTRACT:

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with incidence and mortality rates rising significantly with age. Tobacco use is the primary risk factor, aging itself introduces biological and clinical complexities that influence lung cancer risk, diagnosis, treatment, and prognosis. Age-related factors such as cumulative exposure to carcinogens, genetic and epigenetic alterations, immunosenescence, and comorbidities contribute to increased susceptibility and poorer outcomes in older adults. Non-small cell lung cancer (NSCLC) is more prevalent in this population, though genetic predispositions in younger patients also highlight age-stratified molecular differences. Despite therapeutic advances, older patients remain underrepresented in clinical trials. This mini-review also highlights how genetic variants may differentially influence lung cancer risk across age groups, underscoring the importance of age-specific molecular research.

КЉУЧНЕ РЕЧИ / KEYWORDS:

Lung cancer, NSCLC, SNPs, Age

ПРОЈЕКАТ / ACKNOWLEDGEMENT:

This work is funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia, Agreements No. 451-03-136/2025-03/200378.

ЛИТЕРАТУРА / REFERENCES:

  • World Health Organization, Lung cancer, [Internet resource] [Accessed: August 10, 2025]
  • R. L. Siegel, T.B. Kratzer, A.N. Giaquinto, et al., Cancer statistics, 2025, CA: A Cancer Journal for Clinicians, 75 (2025) 10–45.
  • T. Dyba, G. Randi, F. Bray, et al., The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers, European Journal of Cancer (Oxford, England : 1990), 157 (2021) 308–347.
  • American Cancer Society, Key statistics for lung cancer, [Internet resource] [Accessed: August 10, 2025]
  • F. Venuta, D. Diso, I. Onorati, et al., Lung cancer in elderly patients, Journal of Thoracic Disease, 8 (Suppl 11) (2016) S908–S914.
  • GBD 2019 Respiratory Tract Cancers Collaborators, Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019, The Lancet Respiratory Medicine, 9 (2021) 1030–1049.
  • B. Milholland, A. Auton, Y. Suh, J. Vijg, Age-related somatic mutations in the cancer genome, Oncotarget, 6 (28) (2015) 24627–24635.
  • D. J. Zabransky, E.M. Jaffee, A.T. Weeraratna, Shared genetic and epigenetic changes link aging and cancer, Trends in Cell Biology, 32 (4) (2022) 338–350.
  • J. Lian, Y. Yue, W. Yu, et al., Immunosenescence: a key player in cancer development, Journal of Hematology & Oncology, 13 (2020) 151.
  • K. Inamura, Lung cancer: understanding its molecular pathology and the 2015 WHO classification, Frontiers in Oncology, 7 (2017) 193.
  • A. G. Nicholson, M.S. Tsao, M.B. Beasley, et al., The 2021 WHO Classification of Lung Tumors: impact of advances since 2015, Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 17 (3) (2022) 362–387.
  • American Cancer Society, Lung Cancer Survival Rates, [Internet resource] [Accessed: August 10, 2025]
  • F. Tas, R. Ciftci, L. Kilic, S. Karabulut, Age is a prognostic factor affecting survival in lung cancer patients, Oncology Letters, 6 (5) (2013) 1507–1513.
  • M. S. Kale, K. Sigel, A. Arora, et al., The benefits and harms of lung cancer screening in individuals with comorbidities, JTO Clinical snd Research Reports, 5 (3) (2024) 100635a
  • S. Advani, D. Zhang, M. Tammemagi, et al., Comorbidity profiles and lung cancer screening among older adults: U.S. Behavioral Risk Factor Surveillance System 2017–2019, Annals of the American Thoracic Society, 18 (11) (2021) 1886–1893.
  • P. Pacheco, V. Melo, C. Martins, H. Ribeiro, Lung cancer screening with low-dose CT: a systematic review, Cureus, 16 (12) (2024) e75515.
  • G. Wu, X. Gu, D. Yuan, et al., Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old, Translational Cancer Research, 8 (1) (2019) 87–95.
  • N. L. Christensen, A. Gouliaev, S. McPhail, et al., Lung cancer among the elderly in Denmark – a comprehensive population-based cohort study, Lung Cancer, 191 (2024) 107555.
  • G. R. Tarchand, V. Morrison, M.A. Klein, E. Watkins, Use of comprehensive geriatric assessment in oncology patients to guide treatment decisions and predict chemotherapy toxicity, Federal Practitioner : For The Health Care Professionals of The VA, DoD, and PHS, 38 (Suppl 2) (2021) S22–S28.
  • C. O’Leary, L. McSorley, B. Hennessy, et al., Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer, Expert Opinion on Pharmacotherapy, 21 (17) (2020) 2185–2194.
  • N. Giaj-Levra, P. Borghetti, A. Bruni, et al., Current radiotherapy techniques in NSCLC: challenges and potential solutions, Expert Review of Anticancer Therapy, 20 (5) (2020) 387–402.
  • Q. Chen, S. Ying, J. Qin, L. Zhang, Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer, Frontiers in Oncology, 14 (2024) 1384906.
  • S. Meucci, U. Keilholz, D. Heim, et al., Somatic genome alterations in relation to age in lung squamous cell carcinoma, Oncotarget, 9 (2018) 32161–32172.
  • J. Fan, T. Hong, X. Zhao, et al., A two-stage genome-wide association study identified four potential early-onset non-small cell lung cancer risk loci based on 26,652 participants in Chinese population, Molecular Carcinogenesis, 62 (9) (2023) 1263–1270.
  • C. Zhang, Y. Cheng, W. Chen, et al., Association of CYP19A1 rs28757157 polymorphism with lung cancer risk in the Chinese Han population, World Journal of Surgical Oncology, 20 (1) (2022) 400.